Муйдинова дилафруз дилшодбек кизи

Заключение

Выводы


ЛИТЕРАТУРА
1. Балабанова Р. М. Эффективность локальных форм НПВС для купирования боли и воспаления. Ревматология, травматология и ортопедии, 2013,№1, с. 22.
2. Белоусов Ю.Б., Гуревич К.Г. Влияние НПВП и парацетамола на сердечно-сосудистую систему. Клин. фармакологическая терапия. 2002; 5: 5–7 [Belousov IuB, Gurevich KG. Vliianie NPVP i paratsetamola na serdechno-sosudistuiu sistemu. Klin. farmakologicheskaia terapiia. 2002; 5: 5–7 (in Russian)].
3. Доклинические исследования лекарственных веществ : учеб, пособие / А. В. Бузлама [и др.] ; под ред. А. А. Свистунова. — М.: ГЭОТАР-Медиа, 2017. — 384 с.
4.Денисов Л.Н., Прозоровская З.Р. и др. Повышает ли комбинация нестероидных противовоспалительных препаратов и ментола эффективность локальной терапии? Научно практическая ревматология, 2006, №1, с. 1–6.
5.Здравоохранение в России. 2017. Статистический сборник. М.: Росстат; 2017 [Zdravookhranenie v Rossii. 2017. Statisticheskii sbornik. Moscow: Rosstat (in Russian)].
6. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т., и др. Рациональное использование нестероидных противовоспалительных препаратов. Научно-практическая ревматология. 2018; 56 (Прил. 1): 1–29 [Karateev AE, Nasonov EL, Ivashkin VT, et al. Ratsional'noe ispol'zovanie nesteroidnykh protivovospalitel'nykh preparatov. Nauchno-prakticheskaia revmatologiia. 2018; 56 (Pril. 1): 1–29 (in Russian)].180 CONSILIUM MEDICUM. 2021; 23 (2): 175–180.ОБЗОР https://doi.org/10.26442/20751753.2021.2.200727
7. Каратеев А.Е. Комбинация ибупрофена и парацетамола: первая ступень эффективного контроля скелетно-мышечной боли. РМЖ. 2017; 2: 1562–6 [Karateev AE. Kombinatsiia ibuprofena i paratsetamola: pervaia stupen' effektivnogo kontrolia skeletno-myshechnoi boli. RMZh. 2017; 2: 1562–6 (in Russian)].
8. Каратеев А.Е., Яхно Н.Н., Лазебник Л.Б., и др. Применение нестероидных противовоспалительных препаратов. Клинические рекомендации. М.: ИМА-ПРЕСС, 2009 [Karateev AE, Yakhno NN, Lazebnik LB, et al. The use of non-steroidal anti-inflammatory drugs. Clinical guidelines. Moscow: IMA-PRESS (in Russian)].
9. Каратеев А.Е.с соавт.Рациональное применение нестероидных противовоспалительных препаратов в клинической практике. Клинические рекомендации. Современная ревматология, 2015, с. 1-10.
10. Клиническая фармакокинетика. Практика дозирования лекарств: Спец. выпуск Б43 серии «Рациональная фармакотерапия» / Ю. Б. Белоусов, К. Г. Гуревич. — М.: Литтерра, 2005. — 288 с.
11. Лабораторные животные. Разведение, содержание, использование в эксперименте. Западнюк И.П., Западнюк В.И., Захария Е.А. Западнюк Б. В.-3-е изд. перераб.и доп. Киев: Вище школа. Головное изд-во, 1983-383 с.1
12. Раменская Г.В., Шохин И.Е., Кулинич Ю.И. Классификации лекарственных веществ по их биофармацевтическим свойствам – БКС и BDDCS. Вестник ВГУ. Химия. Биология. Фармация. 2012; 1: 212–5 [Ramenskaia GV, Shokhin IE, Kulinich IuI. Klassifikatsii lekarstvennykh veshchestv po ikh biofarmatsevticheskim svoistvam – BKS i BDDCS. Vestnik VGU. Khimiia. Biologiia. Farmatsiia. 2012; 1: 212–5 (in Russian)].
13. Миронов А.Н., Руководство по проведению доклинических исследований лекарственных средств. Часть первая. — М.: Гриф и К, 2012. — 944 с.
14. С.А.Чубатова, В.С.Тульский, Ю.Г.Жуковский, В.А.Жуковская Активные ингредиенты и система их доставки в косметических средствах репарирующего действия // Экспериментальная и клиническая дерматокосметология. – 2004. - № 1. – С. 15-20
15. Саноцского И.В. Под. Ред. Методы определения токсичности и опасности химических веществ. - М., 1970. - С. 50-54.
16. Сернов Л.Н., Гацура В.В. ЭЛЕМЕНТЫ ЭКСПЕРИМЕНТАЛЬНОЙ ФАРМАКОЛОГИИ.М., 2000. 352 с.
17.Сигидин Я.А., Шварц Г.Я., Арзамасцев А.П., Либерман С.С. — Лекарственная терапия воспалительного процесса (экспериментальная и клиническая фармакология противовоспалительных препаратов). — М.: Медицина, — 1988, — 240 с.
18.Соболев, А.С. Внутриклеточный транспорт и его использование для направленной внутриклеточной доставки локально действующих лекарств /А.С. Соболев, А.А. Розенкранц //Проблемы регуляции в биологических системах /под ред. А.Б. Рубина. – Ижевск, 2006. – 480 с.
19.Сюбаев Р.Д.,Шварц Г.Я. Бюл.эксперим. биол. и мед., 1986. — № 12. — С. 733–735.
20. Сюбаев Р.Д., Машковский М.Д., Шварц Г.Я. и соавт. Хим.-фарм.журнал, 1986. — № 1. — С. 33–39.
21.Тихонов Н.Г., Перепелкин А.И. Лечение бронхопневмонии с/х животных липосомальным стрептомицином //Проблемы биологической и экологической безопасности. Материалы Международной научной конф. (22- 24 мая 2000 г., Оболенск). - С. 147.


22.Топчий Н. В., Топорков А. С. Оптимизация применения нестероидных противовоспалительных препаратов в общемедицинской практике // РМЖ. 2011; 19 (2): 27–32.

23. Филипович-Сосновска А. Новости фармации и медицины. — 1997. — № 5–6. — С. 89–94.

24. Шварц Г.Я. Хим.-фарм. журн. — 1988, № 11. — С. 1317–1326.
25. Шварц Г.Я., Пасхина Т.С., Якубовская Р.И. Фармакол. и токсикол. — 1984. — № 4. — С. 74–81.
26.Эффективность липосомальной лекарственной формы антибактериальных препаратов в ингаляционной терапии экспериментального тубер­ кулеза /Ю.Н. Курунов, В.А. Краснов, А.В. Свистельник и др. //Пробл. туберкулеза. – 1995. – № 1. – С. 38­40.
27. Adatia A, Rainsford KD, Kean WF. Osteoarthritis of the knee and hip. Part II: therapy with ibuprofen and a review of clinical trials. J Pharm Pharmacol. 2012; 64 (5): 626–36. DOI: 10.1111/j.2042-7158.2012.01456.x
28.Ahmad N., Grad H. A., Haas D. A., Aronson K. J., Jokovic A., Locker D. The efficacy of nonopioid analgesics for postoperative dental pain: a meta-analysis // Anesth Prog. 1997, Fall; 44 (4): 119–26. PubMed PMID: 9481955; PubMed Central PMCID: PMC2148941.

29. Alexander L, Hall E, Eriksson L, Rohlin M. The combination of non-selective NSAID 400 mg and paracetamol 1000 mg is more effective than each drug alone for treatment of acute pain. A systematic review. Swed Dent J. 2014; 38 (1): 1–14.

30. Al-Saidan SM. Transdermal self-permeation enhancement of ibuprofen. J Control Release. 2004; 100(2): 199–-209
31. Atkinson HC, Stanescu I, Frampton C, et al. Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration. Clin Drug Investig. 2015; 35 (10): 625–32. DOI: 10.1007/s40261-015-0320-8 43. Tanner T, Aspley S, Munn A, Thomas T. The pharmacokinetic profile of a novel fixed-dose combination tablet of ibuprofen and paracetamol. BMC Clin Pharmacol. 2010; 10: 10. DOI: 10.1186/1472-6904-10-10
32. A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide­targeted liposomes /J.F. Stefa­ nick, J.D. Ashley, T. Kiziltepeet et al. //ACS Nano. – 2013. – V. 7(4). – P. 2935­2947.
33. ATP­containing imrnunoliposomes specific for cardiac myosin /W. Liang, T. Levchenko, B.A. Khaw et al. //Curr. Drug Deliv. – 2004. – № 1. – P. 1­7.
34. Bendas G, Krause A. Schmidt R, Vogel J, Rothe U. Selectins as new targets for immunoliposome-mediated drug delivery. A potential way of anti-inflammatory therapy // Pharm. Acta Helv. - 1998. - V. 73. – Р.19-26.
35. Blagbrough, I.S. Animal models for target diseases in gene therapy – using DNA and siRNA delivery strategies /I.S. Blagbrough, C. Zara //Pharmace­ ut. Research. – 2009. – V. 26(1). – P. 1­18.
36. Bailey E, Worthington H, Coulthard P. Ibuprofen and/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth, a Cochrane systematic review. Br Dent J. 2014; 216 (8): 451–5. DOI: 10.1038/sj.bdj.2014.330
37. Barkin RL. Topical Nonsteroidal Anti-Inflammatory Drugs: The Importance of Drug, Delivery, and Therapeutic Outcome. Am J Ther. 2015; 22(5): 388-407. doi: 10.1097/MJT.0b013e3182459abd.
38. Becker M. C. et al. PRECISION Investigators. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis // Am Heart J. 2009, Apr; 157 (4): 606–612. Epub 2009, Feb 25. PubMed PMID: 19332185.

39. Boureau F, Schneid H, Zeghari N, et al. The IPSO study: ibuprofen, paracetamol study in osteoarthritis. A randomised comparative clinical study comparing the efficacy and safety of ibuprofen and paracetamol analgesic treatment of osteoarthritis of the knee or hip. Ann Rheum Dis. 2004; 63 (9): 1028–34.

40. Bradley R, Ellis P, Thomas P, et al. A randomized clinical trial comparing the efficacy of ibuprofen and paracetamol in the control of orthodontic pain. Am J Orthod Dentofacial Orthop. 2007; 132 (4): 511–7.
41. Bjarnason I, Sancak O, Crossleyet A, et al. Differing disintegration and dissolution rates, pharmacokinetic profiles and gastrointestinal tolerability of over the counter ibuprofen formulations. J Pharm Pharmacol. 2018; 70 (2): 223–33. DOI: 10.1111/jphp.12827
42. Bjarnason I. Ibuprofen and gastrointestinal safety: a dose-duration-dependent phenomenon // J R Soc Med. 2007; 100 Suppl 48: 11–14.
43. Brooks P.M., Day R.O. New Engl. J. Med., 1991. — Vol. 324. — P. 1716–1725.
44. Brune K, Hinz B. The discovery and development of anti-inflammatory drugs. Arthritis Rheum. 2004; 50: 2391–9
45. Castelnuovo E. et al. TOIB study team. Cost-effectiveness of advising the use of topical or oral ibuprofen for knee pain; the TOIB study Rheumatology (Oxford) 2008; 47 (7): 1077–1081.
46. Corrias, F. New methods for lipid nanoparticles preparation /F. Corrias, F. Lai //Recent Pat Drug Deliv. Formul. – 2011. – V. 5(3). – P. 201­213.
47. Codispoti J, Prior M, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache: a randomized controlled trial. Headache. 2001; 41 (7): 665–79.
48. Cohen P. Non-steroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions. Br Med J. 1986; 293 (6538): 51. DOI: 10.1136/bmj.293.6538.51a
49. Cooper R, Booker C, Spanswick C. What is pain management, and what its relevance to the rheumatologist? Rheumatology (Oxford). 2003; 42: 1133–7.
50.Damen L. et al. Symptomatic treatment of migraine in children: a systematic review of medication trials // Pediatrics. 2005, Aug; 116 (2): e295–302. Review. PubMed PMID: 16061583.
51. Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral ibuprofen for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009: CD001548.
52. Derry CJ, Derry S, Moore RA. Single dose oral ibuprofen plus paracetamol (acetaminophen) for acute postoperative pain. Cochrane Database Syst Rev. 2013; 6: CD010210. DOI: 10.1002/14651858.CD010210.pub2
53. Derry S., Moore A., Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2014; 9: CD007400. doi:10.1002/14651858.CD007400.pub2.
54. Derry S., Conaghan P., Da Silva J. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016 Apr 22;4:CD007400. doi: 10.1002/14651858.CD007400.pub3.

55. DeWitt D.L., Meade E.A., Smith W.L. — Amer. J. Med., 1993, — Vol. 95. — Suppl.2A. — P. 40S–44S.

56. Dreiser R, Marty M, Ionescu E, et al. Relief of acute low back pain with diclofenac-K 12.5 mg tablets: a flexible dose, ibuprofen 200 mg and placebo-controlled clinical trial. Int J Clin Pharmacol Ther. 2003; 41 (9): 375–85.
57. Derycke, A.S. Liposomes for photodynamic therapy /A.S. Derycke, P.A. de Witte //Adv. Drug Deliv. Rev. – 2004. – V. 56. – P. 17­30. 15T. 13 № 2 2014
58. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages /S.P. Vyas, M.E. Kannan, S. Jain et al. //Int. J. Pharmaceu­ tics. – 2004. – V. 269, N 1. – P. 37­49. 72. Efficacy of liposomal budesonide in experimental asthma /K.S. Konduri et al. //J. Allergy Clin. Immun. – 2003. – V. 111. – P. 321­327.
59. Daniels SE, Goulder MA, Aspley S, Reader S. A Randomised, Five-Parallel-Group, Placebo-Controlled Trial Comparing the Efficacy and Tolerability of Analgesic Combinations Including a Novel Single-Tablet Combination of Ibuprofen/Paracetamol for Postoperative Dental Pain. Pain. 2011; 152 (3): 632–42.
60. Doherty M, Hawkey C, Goulder M, et al. A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain. Ann Rheum Dis. 2011; 70 (9): 1534 DOI: 10.1136/ard.2011.154047
61. Ed. Kamm M.A., Lennard-Jones J.E. Constipation // Wrighston Biomedical Publishing LTD, USA, 1994.
62. Ekman E, Fiechtner J, Levy S, Fort J. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop. 2002; 31 (8): 445–51.
63. Emery P. Considerations for nonsteroidal anti-inflammatory drug therapy: benefits. Scand J Rheumatol. 1996; 25 (Suppl. 105): 5–12.
64. Epidermal growth factor receptor (EGFR) – targeted imrnunoliposomes mediate specific and efficient drug delivery to EGFR­ and EGFRvlll­overexpres­ sing tumor cells /C. Mamot et al. //Cancer Res. – 2003. – V. 63. – P. 3154­3161.
65.Evers S., Afra J., Frese A., Goadsby P. J., Linde M., May A., Sandor P. S. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine — revised report of an EFNS task force // Eur J Neurol. 2009, Sep; 16 (9): 968–981. PubMed PMID: 19708964.

66. Factors governing the in vivo tissue uptake of transferrin–coupled polyethylene glycol liposomes in vivo /H. Hatakeyama, H. Akita, K. Maruyama et al. //Int. J. Pharm. – 2004. – V. 281. – P. 25­33.

67. Fang, J.Y. Nanoparticles as delivery carriers for anticancer prodrugs /J.Y. Fang, S.A. al­Suwayeh //Expert opinion on drug delivery. – 2012. – V. 9(6). – P. 657­669.
68. Farkouh M, Kirshner H, Harrington R. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004; 364: 675–84.
69. Fitzcharles MA, Almahrezi A, Shir Y. Pain: understanding and challengers for the Rheumatologist. Arthritis Rheum. 2005; 52: 3685–92.
70. Gabizon, A. Emerging role of liposomal drug carrier systems in cancer chemotherapy /Gabizon A. //J. Uposome Res. – 2003. – V. 13. – P. 17­20.
71. Hersh E. V., Kane W. T., O’Neil M. G., Kenna G. A., Katz N. P., Golubic S., Moore P. A. Prescribing recommendations for the treatment of acute pain in dentistry // Compend Contin Educ Dent. 2011, Apr; 32 (3): 22, 24–30; quiz 31–2. PubMed PMID: 21560740.

72. Jin, C.S. Liposomal nanostructures for photosensitizer delivery /C.S. Jin, G. Zheng //Lasers Surg. Med. – 2011. – V. 43(7). – P. 734­748.

73. Katz JN, Smith SR, Collins JE, et al. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthrit Cartil. 2016; 24 (3): 409–18. DOI: 10.1016/j.joca.2015.10.006
74.Koster R., Anderson M., de Beer E. «Fed. Proc.», 1959. — Vol. 18. — P. 412.
75. Laska EM, Sunshine A, Marrero I, et al. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther. 1986; 40: 1–7.
76.Lain L. Approaches to nonsteroidal antiinflammatory drug use in high-risk patient. Gastroenterology. 2001;120: 594–606.
77. Kapoor, M. Physicochemical characterization techniques for lipid based delivery systems for siRNA /M. Kapoor, D.J. Burgess, S.D. Patil //Int. J. Pharm. – 2012. – V. 427(1). – P. 35­57.
78. Klibanov, A.L. Long­circulating sterically protected liposomes /A.L. Klibanov, V.P. Torchilin, S. Zalipsky //In V.P. Torchilin, V. Weissig, eds. Liposomes: Practical Approach. – Oxford, UK, Oxford University Press, 2003. – Р. 231­265.
79. Loux J., de Palma P., Yanksell S. «Toxicol. Appl. Pharmacol.», 1972. — Vol. 22. — P. 672.
80. Liposome transduction into cells enhanced by haptotactic peptides (Haptides) homologous to fibrinogen C­termini /R. Gorodetsky et al. //J. Control. Release. – 2004. – V. 95. – P. 477­488.
81. Lo, Y.L. Liposomes and disaccharides as carriers in spray­dried powder formulations of superoxide dismutase /Y.L. Lo, J.C. Tsai, J.H. Kuo //J. Control. Release. – 2004. – V. 94. – P. 259­272. 27. Maxfield, F.R. Endocytic recycling /F.R. Maxfield, T.E. McGraw //Nat. Rev. Mol. Cell Biol. – 2004. – N 5. – P. 121­132.
82.Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015; 55 (1): 3–20. DOI: 10.1111/head.12499
83.Masso Gonzalez E. L. et al. Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding // Arthritis Rheum. 2010 Jun; 62 (6): 1592–1601. PubMed PMID: 20178131.

84. Moghimi, S.M. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein­binding properties /S.M. Moghimi, J. Szebeni //Prog. Lipid Res. – 2003. – V. 42. – P. 463­478.

85. Morales, J.O. Surfactants: their critical role in enhancing drug delivery to the lungs /J.O. Morales, J.I. Peters, R.O. Williams III //Therapeutic Delivery. – 2011. – N 5. – P. 623­641.
86. Multifunctional Pharmaceutical Nanocarriers /Ed. V. Torchilin. – Springer Science + Business Media, LLC, 2008. – 473 p.
87. Meier R., Schuler W., Dessaulles P. «Experientia», 1950. — Vol. 6. — P. 469.
88. Mehlisch DR, Sykes J. Ibuprofen blood plasma levels and onset of analgesia. Int J Clin Pract. 2013; 67: 3–8.
89. Mehlisch DR, Asple S, Daniels SE, et al. A Single-Tablet Fixed-Dose Combination of Racemic Ibuprofen/Paracetamol in the Management of Moderate to Severe Postoperative Dental Pain in Adult and Adolescent Patients: A Multicenter, Two-Stage, Randomized, Double-Blind, Parallel-Group, PlaceboControlled, Factorial Study. Clin Ther. 2010; 32: 1033–49.
90. Moore AR. Faster, higher, stronger? Evidence for formulation and efficacy for ibuprofen in acute pain. Pain. 2014; 155 (1): 14–21. DOI: 10.1016/j.pain.2013.08.013
91. Milsom I, Minic M, Dawood M, et al. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clin Ther. 2002; 24 (9): 1384–400.
92. Moore PA, Hersh EV. Combining ibuprofen and acetaminophen for acute pain management after third-molar extractions: translating clinical research to dental practice. J Am Dent Assoc. 2013; 144 (8): 898–908. DOI: 10.14219/jada.archive.2013.0207
93. Moore R, Derry S, McQuay H, Wiffen P. Single dose oral analgesics for acute postoperative pain in adults. Cochrane Database Syst Rev. 2011; 9: CD008659.
94. Moore RA, Wiffen PJ, Derry S, et al. Non-prescription (OTC) oral analgesics for acute pain – an overview of Cochrane reviews. Cochrane Database Syst Rev. 2015; 11: CD010794. DOI: 10.1002/14651858.CD010794.pub2
95. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase. JAMA. 2006; 296: 1633–44.
96. Nissen S., Yeomans N., Solomon D. et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016; 375(26): 2519-29. doi: 10.1056/NEJMoa1611593.
97. Nanocarrier possibilities for functional targeting of bioactive peptides and proteins: state­of­the­art / C.G. Moutinho, C.M. Matos, J.A. Teixeira et al. //J. Drug Target. – 2012. – V. 20(2). – P. 114­141.
98. Okeley N.M., Gelb M. H. A designed probe for acidic phospholipids reveals the unique enriched anionic character of the cytosolic face of the mammalian plasma membrane // J. Biol. Chem. 2004.- V. 279.- P. 21833-21840.
99. Ostojic P, Radunovic G, Lazovic M, Tomanovic-Vujadinovic S. Ibuprofen plus paracetamol versus ibuprofen in acute low back pain: a randomized open label multicenter clinical study. Acta Reumatol Port. 2017; 42 (1): 18–25.
100. Ong CK, Seymour RA, Lirk P, Merry AF. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg. 2010; 110 (4): 1170–9. DOI: 10.1213/ANE.0b013e3181cf9281
101. Peer, D. Loading mitomycin C inside long circulating hyaluronan targeted nano­liposomes increases its antitumor activity in three mice tumor models /D. Peer, R. Margalit //Int. J. Cancer. – 2004. – V. 108. – P. 780­789.
102.Rainsford K. D. Fifty years since the discovery of ibuprofen // Inflammopharmacology. 2011, Dec; 19 (6): 293–297. PubMed PMID: 22120888.

103. Randall L., Selitto J. «Arch. Int. Pharmacodyn.», 1957. — Vol. 111. — P 209.

104. Rabbie R, Derry S, Moore RA, McQuay HJ. Ibuprofen with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev. 2010; 10: CD008039. DOI: 10.1002/14651858.CD008039.pub2
105. Rampal P, Moore N, Van Ganse E, et al. Gastrointestinal tolerability of ibuprofen compared with paracetamol and aspirin at over-the-counter doses. J Int Med Res. 2002; 30 (3): 301–8.
106. Recent advances in liposomal dry powder formulations: preparation and evaluation /A. Misra, K. Jinturkar, D. Patel et al. //Expert Opin. Drug. Deliv. – 2009. – V. 6(1). – P. 71­89.
107. Richy F. et al. Time dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach // Ann Rheum Dis. 2004, Jul; 63 (7): 759–766. Review. PubMed PMID: 15194568; PubMed Central PMCID: PMC1755051.

108. Russell R. I. Non-steroidal anti-inflammatory drugs and gastrointestinal damage-problems and solutions // Postgrad Med J. 2001; 77 (904): 82–88.

109. Saino V., Monti D., Burgalassi S. et al. Optimization of skin permeation and distribution of ibuprofen by using nanostructures (coagels) based on alkyl vitamin C derivatives. Eur J Pharm Biopharm. 2010 Nov; 76(3):443-9. doi: 10.1016/j.ejpb.2010.08.004.

110. Serum­stable and long­circulating, PEGylated, pH–sensitive liposomes /E. Roux, C. Passiran, S. Scheffold et al. //J. Control. Release. – 2004. – V. 94. – P. 447­451.
111. Silverstein F, Faich G, Goldstein J, et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000; 284: 1247–55.
112.Skalko N., M.Cajkovac, I.Jelsenjak. Liposomes with clindamycin hydrochloride in the therapy of acne vulgaris // Int. J.Pharmaceulics. - 1993. - V.85 – Р. 97-101.
113. Sofou, S. Antibody­targeted liposomes in cancer therapy and imaging /S. Sofou, G. Sgouros //Expert Opin. Drug. Deliv. – 2008. – V. 5(2). – P. 189­204.
114. Sörgel F, Fuhr U, Minic M, et al. Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation. Int J Clin Pharmacol Ther. 2005; 43 (3): 140–9. DOI: 10.5414/cpp43140
115. Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother. 2007; 41 (11): 1782–91
116. Strom B, Schinnar R, Bilker W, et al. Gastrointestinal tract bleeding associated with naproxen sodium vs ibuprofen. Arch Intern Med. 1997; 157 (22): 2626–31.
117. Swingle K., Hamilton R., Harrington J., Kvam D. «Arch. Int. Pharmacodyn.», 1971. — Vol. 189. — P. 129.
118. Targeted drug delivery using immunoconjugates: principles and applications /M.V. Pasquetto, L. Vecchia, D. Covini et al. //J. Immunother. – 2011. – V. 34(9). – P. 611­628.
119. Taurin, S. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link? /S. Taurin, H. Nehoff, K. Greish //J. Control Release. – 2012. – V. 164(3). – P. 265­275.
120.Towheed T. E., Maxwell L., Judd M. G., Catton M., Hochberg M. C., Wells G. Acetaminophen for osteoarthritis // Cochrane Database Syst Rev. 2006, Jan 25; (1): CD004257. Review. PubMed PMID: 16437479.
121. Tiso R. L., Tong-Ngork S., Fredlund K. L. Oral versus topical Ibuprofen for chronic knee pain: a prospective randomized pilot study // PainPhysician. 2010; 13 (5): 457–467.

122. Torchilin, V.P. Recent advances with liposomes as pharmaceutical carriers /V.P. Torchilin //Nature Reviews Drug Discovery. – 2005. – V. 4, N 2 – P. 145­160.

123. Torchilin, V.P. Surface modification of liposomes /V.P. Torchilin, V. Weissig //Liposomes: Practical Approach. – Oxford, UK, Oxford University Press, 2003. – Р. 193­229.
124. Toxicological profile of therapeutic nanodelivery systems /L.M. Bimbo, L. Peltonen, J. Hirvonen, H.A. Santos //Curr. Drug. Metab. – 2012. – V. 13(8). – P. 1068­1086.
125. Transferrin­modified liposomes equipped with a pH–sensitive fusogenic peptide: an artificial viral–like delivery system /T. Kakudo et al. //Biochem. – 2004. – V. 43. – P. 5618­5628.
126.Trimble J., Light B. Effect of Penetration Enhancers on the Percutaneous Delivery of Pain Management Actives. Int J Pharm Compd. 2016; 20(3): 250–256.

127.Tumor cell targeting of liposome–entrapped drugs with phospholipid–anchored folic acid–PEG conjugates /A. Gabizon, H. Shmeeda, A.T. Horowitz et al. //Adv. Drug Deliv. Rev. – 2004. – V. 56. – P. 1177­1192.

128.Underwood M., Ashby D., Cross P. et al. Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study // BMJ. 2008; 336 (7636): 138–142.

129. Ushkalova E.A., Zyryanov S.K., Zalolochina K.E. Safety and tolerability of nsaids: focus on aceclofenac. Meditsinskiy sovet = Medical Council. 2019;(9):110-. (In Russ.) https://doi.org/10.21518/2079-701X-2019-9-110-120
130. Van Winden, E.C. Freezy­drying of liposomes: theory and practice /E.C. Van Winden //Meth. Enzym. – 2003. – V. 367. – P. 99­110.
131. Whitefield M., O’Kane C. J., Anderson S. Comparative efficacy of a proprietary topical ibuprofen gel and oral ibuprofen in acute soft tissue injuries: a randomized, double-blind study // J Clin Pharm Ther. 2002; 27 (6): 409–417.

132. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013; 22: 559–70. DOI: 10.1002/pds

133. Yang M., Wang H.-T., Zhao M. et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015; 94; 40: P15-
12576. DOI: 10.1097/MD.0000000000001592
Источники

1. 
   https://cyberleninka.ru/
   
2. 
   http://e-library.ru
   
3. 
   https://scholar.google.com/schhp?hl=ru&as_sdt=0,5
   
4. 
   https://doi.org/10.21518/2079-701X-2019-9-110-120
   

Термины и обозначения
ЛЛТВ - лекарственные формы для локального трансдермального введения
АК-активный компонент
НПВП-нестероидные противовоспалительные препараты
ЦОГ-циклооксигеназа